BeOne Medicines raises 2026 revenue guidance to $6.9B-$7.0B after third-quarter report
The drugmaker also lifted its GAAP and non-GAAP operating income forecasts, as third-quarter revenue reached $1.89B and earnings per share $4.59.
BeOne Medicines raised its forecast for 2026 revenue to $6.9bn to $7.0bn, up from $6.6bn to $6.8bn, as it reported third-quarter revenue of $1.89bn and earnings of $4.59 a share.
The profit forecasts went up as well. BeOne now expects GAAP operating income of $1.2bn to $1.3bn, up from $1.0bn to $1.1bn. Its non-GAAP operating income forecast is $1.9bn to $2.0bn, up from $1.7bn to $1.8bn.
Raising sales and profit forecasts together suggests the company sees a broad improvement across the year, not a gain in one line. It is management's own forecast, but a raised outlook says more than a single strong quarter.
John V. Oyler, co-founder, chairman and chief executive, said the growth and the higher guidance reflect global expansion and leadership in hematology, the treatment of blood disorders. He named two drugs as the drivers: BRUKINSA and the newer BCL2 inhibitor BEQALZI.
The higher range also sets a higher bar for the remaining months of 2026.
© Raydn · raydn.us